S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
Why is Russia reopening dormant copper mines? (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
Why is Russia reopening dormant copper mines? (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
Why is Russia reopening dormant copper mines? (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
S&P 500   3,998.84
DOW   33,947.10
QQQ   287.64
All the Cloud Storage You Need Is on Sale for the Holidays
Why is Russia reopening dormant copper mines? (Ad)
Tesla Shares Are Sliding, Here’s Why
Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
China Threat Triggers Potential Mining Boom for Investors (Ad)
Lockheed teams with Israel's Rafael on laser defense
Russian oil price cap, EU ban aim to limit Kremlin war chest
Why is Russia reopening dormant copper mines? (Ad)
World Cup fans find booze at hotels, Qatar's 1 liquor store
3 Signs the Stock Market Outlook is Improving
NASDAQ:PTGX

Protagonist Therapeutics - PTGX Stock Forecast, Price & News

$7.80
-0.27 (-3.35%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.75
$8.05
50-Day Range
$7.36
$8.83
52-Week Range
$6.91
$37.04
Volume
643,806 shs
Average Volume
957,286 shs
Market Capitalization
$383.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.50

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
316.7% Upside
$32.50 Price Target
Short Interest
Healthy
4.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of Protagonist Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.60) to ($3.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

562nd out of 1,033 stocks

Pharmaceutical Preparations Industry

261st out of 502 stocks

PTGX stock logo

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Stock News Headlines

PTGX Protagonist Therapeutics, Inc.
PTGX, MNKD and AVGO are among after hour movers
See More Headlines
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Company Calendar

Last Earnings
11/08/2022
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTGX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.50
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+316.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-125,550,000.00
Net Margins
-291.70%
Pretax Margin
-369.64%

Debt

Sales & Book Value

Annual Sales
$27.36 million
Book Value
$6.29 per share

Miscellaneous

Free Float
46,591,000
Market Cap
$383.74 million
Optionable
Not Optionable
Beta
2.27

Key Executives

  • Dr. Dinesh V. Patel Ph.D. (Age 65)
    CEO, Pres, Sec. & Director
    Comp: $1.04M
  • Dr. David Y. Liu Ph.D. (Age 72)
    Chief R&D Strategy Officer
    Comp: $702.87k
  • Dr. Suneel K. Gupta Ph.D. (Age 64)
    Chief Devel. Officer
    Comp: $698.72k
  • Dr. Richard S. Shames (Age 62)
    Clinical Advisor
  • Mr. Asif Ali
    Exec. VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh
    Exec. VP & CTO
  • Mr. Matthew M. Gosling (Age 51)
    Exec. VP & Gen. Counsel
  • Ms. Carena Spivey
    Exec. Director of HR
  • Dr. Ashok Bhandari Ph.D. (Age 58)
    Sr. VP of Discovery Chemistry & Process Research
  • Dr. Scott Eric Plevy M.D.
    Exec. VP and Therapeutic Head of Gastroenterology













PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings
or view top-rated stocks.

What is Protagonist Therapeutics' stock price forecast for 2023?

4 brokers have issued twelve-month price targets for Protagonist Therapeutics' shares. Their PTGX share price forecasts range from $21.00 to $41.00. On average, they anticipate the company's stock price to reach $32.50 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for PTGX
or view top-rated stocks among Wall Street analysts.

How have PTGX shares performed in 2022?

Protagonist Therapeutics' stock was trading at $34.20 on January 1st, 2022. Since then, PTGX stock has decreased by 77.2% and is now trading at $7.80.
View the best growth stocks for 2022 here
.

When is Protagonist Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our PTGX earnings forecast
.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) issued its earnings results on Tuesday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.30. Protagonist Therapeutics had a negative trailing twelve-month return on equity of 46.74% and a negative net margin of 291.70%.

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include State Street Corp (9.51%), RTW Investments LP (8.49%), Farallon Capital Management LLC (7.42%), BlackRock Inc. (7.04%), Vanguard Group Inc. (5.98%) and Point72 Asset Management L.P. (5.16%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel, Harold E Selick and Sarah B Noonberg.
View institutional ownership trends
.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $7.80.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $383.74 million and generates $27.36 million in revenue each year. The company earns $-125,550,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 12/6/2022 by MarketBeat.com Staff